Caxton Associates LLP Amicus Therapeutics, Inc. Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 58,114 shares of FOLD stock, worth $345,778. This represents 0.02% of its overall portfolio holdings.
Number of Shares
58,114Holding current value
$345,778% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding FOLD
# of Institutions
315Shares Held
319MCall Options Held
378KPut Options Held
575K-
Wellington Management Group LLP Boston, MA29.2MShares$174 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.1MShares$173 Million0.0% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$145 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY21.5MShares$128 Million7.33% of portfolio
-
Avoro Capital Advisors LLC New York, NY20.5MShares$122 Million2.71% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $1.67B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...